Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine by Gulati, Sunita et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-11-05 
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic 
Candidate Gonococcal Vaccine 
Sunita Gulati 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Amino Acids, Peptides, and Proteins Commons, Bacterial Infections and Mycoses 
Commons, Immunology of Infectious Disease Commons, Immunoprophylaxis and Therapy Commons, 
Infectious Disease Commons, Microbiology Commons, Public Health Commons, and the Therapeutics 
Commons 
Repository Citation 
Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak N, DeOliveira RB, Shaughnessy J, Reed 
GW, Ram S, Rice PA. (2019). Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate 
Gonococcal Vaccine. Open Access Articles. https://doi.org/10.1128/mBio.02552-19. Retrieved from 
https://escholarship.umassmed.edu/oapubs/4068 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic
Candidate Gonococcal Vaccine
Sunita Gulati,a Michael W. Pennington,b Andrzej Czerwinski,c Darrick Carter,d Bo Zheng,a Nancy A. Nowak,a
Rosane B. DeOliveira,a Jutamas Shaughnessy,a George W. Reed,a Sanjay Ram,a Peter A. Ricea
aDepartment of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
bAmbioPharm, Inc., North Augusta, South Carolina, USA
cPeptides International Inc., Louisville, Kentucky, USA
dInfectious Diseases Research Institute, Seattle, Washington, USA
ABSTRACT The global spread of multidrug-resistant strains of Neisseria gonorrhoeae
constitutes a public health emergency. With limited antibiotic treatment options,
there is an urgent need for development of a safe and effective vaccine against
gonorrhea. Previously, we constructed a prototype vaccine candidate comprising a
peptide mimic (mimitope) of a glycan epitope on gonococcal lipooligosaccharide
(LOS), recognized by monoclonal antibody 2C7. The 2C7 epitope is (i) broadly ex-
pressed as a gonococcal antigenic target in human infection, (ii) a critical require-
ment for gonococcal colonization in the experimental setting, and (iii) a virulence
determinant that is maintained and expressed by gonococci. Here, we have synthe-
sized to 95% purity through a relatively facile and economical process a tetrapep-
tide derivative of the mimitope that was cyclized through a nonreducible thioether
bond, thereby rendering the compound homogeneous and stable. This vaccine can-
didate, called TMCP2, when administered at 0, 3, and 6 weeks to BALB/c mice at ei-
ther 50, 100 or 200 g/dose in combination with glucopyranosyl lipid A-stable oil-in-
water nanoemulsion (GLA-SE; a Toll-like receptor 4 and TH1-promoting adjuvant),
elicited bactericidal IgG and reduced colonization levels of gonococci in experimen-
tally infected mice while accelerating clearance by each of two different gonococcal
strains. Similarly, a 3-dose biweekly schedule (50 g TMCP2/dose) was also effective
in mice. We have developed a gonococcal vaccine candidate that can be scaled up
and produced economically to a high degree of purity. The candidate elicits bacteri-
cidal antibodies and is efficacious in a preclinical experimental infection model.
IMPORTANCE Neisseria gonorrhoeae has become resistant to most antibiotics. The
incidence of gonorrhea is also sharply increasing. A safe and effective antigonococ-
cal vaccine is urgently needed. Lipooligosaccharide (LOS), the most abundant outer
membrane molecule, is indispensable for gonococcal pathogenesis. A glycan epitope
on LOS that is recognized by monoclonal antibody (MAb) 2C7 (called the 2C7
epitope) is expressed almost universally by gonococci in vivo. Previously, we identi-
fied a peptide mimic (mimitope) of the 2C7 epitope, which when configured as an
octamer and used as an immunogen, attenuated colonization of mice by gonococci.
Here, a homogenous, stable tetrameric derivative of the mimitope, when combined
with a TH1-promoting adjuvant and used as an immunogen, also effectively attenu-
ates gonococcal colonization of mice. This candidate peptide vaccine can be pro-
duced economically, an important consideration for gonorrhea, which affects socio-
economically underprivileged populations disproportionately, and represents an
important advance in the development of a gonorrhea vaccine.
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Neisseria gonorrhoeae, the causative agent of the sexually transmitted diseasegonorrhea, has become resistant to almost every antibiotic in clinical use. The
combination of ceftriaxone and azithromycin is the current first-line treatment for
gonorrhea recommended by the Centers for Disease Control and Prevention (CDC) (1).
However, resistance to each of these antibiotics have been reported in several countries
(2–5), which further limits treatment options. In addition, the number of cases of
gonorrhea is increasing rapidly: in 2018, 583,405 cases of gonorrhea were reported to
the CDC, a 63% increase since 2014 and an 82.6% increase since the historic low in 2009
(https://www.cdc.gov/std/stats18/gonorrhea.htm). The World Health Organization esti-
mated that 86.9 million cases of gonorrhea occurred globally in 2016 (63). Therefore,
there is an urgent need for safe and effective vaccines against gonorrhea to prevent the
global spread of multidrug-resistant organisms.
Lipooligosaccharide (LOS) is the most abundant molecule expressed on the gono-
coccal surface and contributes significantly to its pathogenesis. Natural and experimen-
tal gonococcal infection in humans induces the development of anti-LOS antibodies
(6–9), which may provide some protection against reinfection (6). An epitope on LOS
that is expressed by almost every gonococcal isolate in vivo is defined by binding of a
monoclonal antibody (MAb) called 2C7 (7). Binding of MAb 2C7 requires the presence
of lactose extensions simultaneously from heptose I (HepI) and HepII (10); MAb 2C7 can
bind to LOS even in the presence of glycan extensions beyond lactose from HepI (11).
Elaboration of the 2C7 epitope by N. gonorrhoeae requires expression of a phase-
variable LOS glycosyltransferase gene called lgtG (12), which adds the proximal Glc
residue at the 3-position of HepII (expression of the 2C7 epitope is completed by lgtE,
which is constitutively expressed and adds Gal to HepII-linked Glc). Absence of HepII-
linked lactose (and therefore the complete 2C7 structure/epitope) significantly atten-
uates gonococcal infection in the mouse cervicovaginal colonization model (13–15).
2C7 expression therefore may be an important virulence factor that enhances or is
required for gonococcal survival in vivo in humans. Furthermore, we recently showed
that lactose from HepII can be capped with sialic acid (15), which decreases comple-
ment deposition (15) and engages members of the Siglec family of proteins (16) to limit
the host inflammatory response to infection. These functions of sialic acid on lactose
expressed from HepII, together with a fitness requirement for the 2C7 structure, may
explain widespread expression of the 2C7 LOS epitope on N. gonorrhoeae (7, 15), which
is displayed by most gonococci, including 95% of minimally passaged N. gonorrhoeae
clinical isolates in Boston, MA (7), and in 100% of clinical isolates in Nanjing, China (15).
Previously, we showed that a peptide mimic of the 2C7 epitope (a mimitope), when
configured as an octameric “multiantigen peptide” (Octa-MAP) (17) and administered
to BALB/c mice with Sigma MPL adjuvant, elicited bactericidal antibodies (IgG Ab
responses were TH1 skewed) and also attenuated gonococcal vaginal colonization in
the experimental model of infection (13). In this report, we evaluate the candidacy of
the 2C7 mimitope that has now been configured as a stable, highly pure tetrapeptide
and administered with glucopyranosyl lipid A (GLA) formulated in a stable oil-in-water
nanoemulsion (SE), an adjuvant approved for use in humans. This study is an important
step in the development of a safe, effective, and economical gonococcal vaccine.
RESULTS
Characterization of a lead vaccine candidate, TMCP2. Initial synthesis of our
vaccine candidate, a multivalent antigenic peptide that encompassed 8 individual
copies of the mimitope of the 2C7 epitope (termed PEP1) onto a lysine core (13),
yielded a heterogenous compound because reversible disulfide bonding occurred
between the terminally located Cys residues on PEP1—internally within the same
molecule and externally to other like molecules, resulting in a pattern of extreme
molecular weight (MW) heterogeneity (see Table S1a in the supplemental material). In
order to synthesize a stable homogenous compound potentially suitable for clinical
use, several strategies were undertaken, further documented in the supplemental
material (Text S1, Table S1, Table S2, Fig. S1A to C). A final stable compound that
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circularized the mimitope via a stable nonreducible (covalent) thioether bond between
the terminal cysteines in linear PEP1 formed the cyclized peptide, renamed monomeric
cyclic peptide 2 (CP2). CP2 was linked to each of four lysines in a scaffold where –NH2
groups on lysines, in turn, were linked to –COOH groups on glutamate molecules in a
core that formed the basis of the tetrameric CP2 structure, called TMCP2 (Fig. 1A). The
purity of TMCP2 determined by reverse-phase high-performance liquid chromatogra-
phy (RP-HPLC) separation showed a major peak (99% of the total area) at 13.155 min
(Fig. S1D). The identity of TMCP2 was verified with positive electrospray ionization (ESI)
time-of-flight mass spectrometry (TOF MS ES) (Fig. S1E). We used enzyme-linked
immunosorbent assay (ELISA) to measure inhibition of binding (residual binding) of
MAb 2C7 that had first been reacted with increasing concentrations of the peptides, to
immobilized gonococcal LOS (Fig. 1B). We observed 50% inhibition of MAb 2C7 binding
to immobilized 15253 LOS in the presence of 25 M and 107 M TMCP2 and CP2,
respectively; the approximately 4-fold lower molar concentration of TMCP2 (compared
to CP2) required to achieve 50% inhibition is consistent with its tetrameric nature. The
overall higher avidity and maintenance of the 4:1 molar ratio in binding experiments
suggested that linking CP2 to the MAP core did not alter antigenicity of the final
compound. Purified LOS, used as a positive control, completely inhibited MAb 2C7
binding to immobilized LOS.
Choice of GLA-SE as the lead adjuvant. Because Sigma MPL cannot be used
clinically, we tested TMCP2 with three additional adjuvants with properties similar to
Sigma MPL: (i) glucopyranosyl lipid adjuvant (GLA) in a stable oil-in-water nanoemul-
sion (SE) (GLA-SE), (ii) GLA-liposome QS21 (GLA-LSQ), and (iii) GLA-aqueous formulation
(GLA-AF) (see Fig. S2 in the supplemental material). Sigma MPL adjuvant was the
control to bridge data from prior experiments. Alum (Alhydrogel) and the stable
oil-in-water nanoemulsion (SE) were also tested. TMCP2 plus GLA-SE or GLA-SQ yielded
FIG 1 Structure and characterization of TMCP2. (A) Chemical structure of TMCP2, the 2C7 mimitope
peptide configured as a tetrameric multiantigenic peptide (MAP). The 2C7 mimitope is indicated in blue.
Cyclization is maintained through a thioether bond. The MAP core is indicated in red and links to each
cyclic peptide through a lysine (K) residue. A schematic of the steps in the synthesis of TMCP2 is shown
in Fig. S1. (B) Inhibition of MAb 2C7 binding to solid-phase-affixed (coated) gonococcal LOS by
monomeric cyclic peptide 2 (CP2), TMCP2, and nominal LOS (control). MAb 2C7 (0.04 g/ml) was added
to microtiter wells coated with LOS purified from gonococcal strain 15253 in the presence of increasing
concentrations of CP2, TMCP2, or LOS (positive control for 100% inhibition). The y axis shows the
percentage of inhibition of MAb 2C7 binding (residual binding) to immobilized LOS in the presence of
the peptide (TMCP2 or CP2) or soluble LOS relative to binding of MAb 2C7 alone to immobilized LOS.
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the highest anti-LOS IgG titers, similar to those elicited by Sigma MPL; GLA-AF gave
intermediate titers, while alum and SE yielded low titers (Fig. S2A).
In light of the importance of complement-dependent killing for the activity of MAb
2C7 in vivo (18), serum bactericidal assays were performed to assess functionality of
immune antibodies. During the course of the antigen optimization and adjuvant
selection studies (performed between mid-2016 and early 2018), we noted that mouse
sera when heat inactivated (56°C for 30 min to deplete endogenous complement) taken
from naive mice or mice given adjuvant alone supported complement-dependent
bactericidal activity against strain FA1090 when normal human serum (NHS) was added
as the source of complement; FA1090 is highly resistant to the bactericidal action of
NHS alone (19). Control mouse sera plus heat-inactivated (56°C for 30 min) NHS failed
to kill gonococci, suggesting that observed killing was complement dependent. A
systematic analysis of the bactericidal activity of heat-inactivated sera with added NHS
from several strains of naive mice was carried out (see Table S3 in the supplemental
material). Except for Rag/ and JhD mice, which both lack antibody, heat-inactivated
sera from all other mice tested supported human complement-dependent killing of N.
gonorrhoeae. Similarly, bactericidal activity was supported by sera from CD1 mice
housed at the Children’s Hospital Oakland Research Institute, Oakland, CA, given alum
adjuvant (20).
Absorption of naive or adjuvant control mouse sera against anti-mouse IgM-linked
agarose, but not protein A/G agarose (depletes IgG), abrogated bactericidal activity
(survival of 80%), revealing IgM as the antibody subclass responsible for the under-
lying bactericidal activity. Mouse sera used in (human) complement-dependent bacte-
ricidal assays in antigen optimization and adjuvant selection studies were therefore
depleted of IgM (Fig. S2). We measured anti-LOS IgG levels in 5 immune sera before and
after passage through anti-mouse IgM agarose and noted that absorption resulted in
a mean decrease in IgG concentration of 13.6% (range, 9.2 to 18.5%).
Serum bactericidal assays with IgM-depleted immune and adjuvant control sera
performed using normal human serum (NHS) as the source of complement (Fig. S2B)
showed that killing of gonococci mirrored anti-LOS IgG titers. Based on these data,
GLA-SE was chosen as the lead adjuvant because it has received approval for human
use (21, 22).
Immunogenicity and bactericidal activity of antisera from mice immunized
with TMCP2 and GLA-SE adjuvant. An initial immunization experiment utilized
inoculation plus boosting at 3 and 6 weeks (3 doses) of 5 mice each with 50, 100, or
200 g (4 mice) of TMCP2 combined with GLA-SE adjuvant. Immunization elicited
anti-LOS IgG responses, measured 2 weeks after final boosting, that exceeded 2 g/ml
in every mouse (Fig. 2A). Post-dose 3 responses in 3 of 5 mice given the 50-g dose
exceeded 10 g/ml. Mice immunized with GLA-SE alone did not elicit IgG responses
against LOS. Specificity was demonstrated by nonreactivity of immune sera with 15253
ΔlgtG LOS (data not shown).
Curiously, the “natural” bactericidal IgM antibodies noted in naive mice or mice
given adjuvants alone seen in the antigen optimization and adjuvant selection studies
were not observed in subsequent experiments (performed after June 2018). Intact
immune sera taken 2 weeks after the last immunization were tested for bactericidal
activity against strain FA1090 (Fig. 2B; numerical data are shown in Table S4A in the
supplemental material). All immune sera showed 50% killing when tested at a final
dilution of 1:6 (immune serum concentration of 16.7%). Mice that received GLA-SE
alone did not show IgG responses against LOS and did not support complement-
dependent bactericidal activity of FA1090 (Table S4A). Depletion of IgM in these sera
did not reduce bactericidal activity significantly, indicating that IgG was responsible for
the bactericidal activity in these immune sera (Table S4A).
In vitro and in vivo efficacy of TMCP2 tested at different doses. In a second,
larger experiment, three groups of female BALB/c mice (n  25 per group) were
immunized using the same protocol used above; a fourth group (n  25) received
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GLA-SE alone. Two weeks after the third immunization, mice in the diestrus phase of
the estrous cycle were treated with Premarin and challenged with N. gonorrhoeae strain
FA1090 (n  6/group) or MS11 (n  6/group). Sera from mice not used for challenge
(n  13 in each group) were collected by cardiac bleeding for immunologic studies (IgG
LOS ELISA and serum bactericidal assays).
Anti-LOS IgG levels were measured in immune sera (n  13 in each group) from
mice not used for challenge experiments. As shown in Fig. 3A, anti-LOS IgG levels in
intact immune sera exceeded 2 g/ml in all mice. The mean anti-LOS IgG levels in the
50-, 100-, and 200-g/dose groups were 4.98, 4.06, and 3.8 g/ml, respectively. As was
shown in the experiment using a smaller number of mice (Fig. 2A), none of the sera
from mice immunized with GLA-SE alone (adjuvant control) showed detectable anti-
gonococcal LOS IgG levels (not shown). We also measured anti-LOS IgM levels in pooled
immune and pooled adjuvant sera (Fig. S3A, i). Similar IgM binding was measured to
15253 LOS (2C7 positive) and 15253 ΔlgtG LOS (2C7 negative) in immune sera and
adjuvant sera, indicating no apparent IgM response to the 2C7 epitope in mice
(Fig. S3A, i). Predictably, passage of sera over anti-mouse IgM agarose abrogated IgM
detection in both immune and adjuvant control sera. We also compared IgG binding to
LOS in the same sera (Fig. S3A, ii); only immune serum, but not adjuvant control serum,
bound 15253 LOS; no IgG binding to 15253 ΔlgtG LOS was detected.
The 13 individual immune sera in each group collected 2 weeks after the 3rd dose
of TMCP2 had been administered were tested for ability to kill FA1090 and MS11 in
complement-dependent serum bactericidal assays. Dose-dependent killing of N. gon-
orrhoeae was seen in all three groups. Notably, all sera, when tested at final concen-
trations of 16.7% (1/6 dilution), resulted in 50% complement-dependent killing
(50% survival) of FA1090 (Fig. 3B). Strain MS11 was more susceptible than FA1090 to
FIG 2 Immunogenicity (A) of TMCP2/GLA-SE and functional activity of elicited antibodies (B). Six-week-old female
BALB/c mice were immunized with three doses of TMCP2 given at 50, 100, or 200 g per dose with GLA-SE
adjuvant (5 g) every 3 weeks or with GLA-SE alone (adjuvant control). The groups immunized with 50 or 100 g
of TMCP2 per dose contained 5 mice each; the group given 200 g/dose of TMCP2 had 4 mice. (A) Antibody levels
against LOS purified from N. gonorrhoeae strain 15253 (elaborates the 2C7 epitope optimally). Anti-LOS IgG levels
against 15253 LOS were measured in sera obtained 2 weeks after each dose. Note the different y axes in the three
graphs. None of the sera showed detectable IgG antibody binding to 15253 ΔlgtG LOS. GLA-SE alone (adjuvant
control) showed no detectable anti-gonococcal LOS IgG. (B) Bactericidal activity of immune sera against N.
gonorrhoeae FA1090. Post-dose 3 sera were tested for their ability to kill N. gonorrhoeae FA1090 using human
complement (16.7% [vol/vol]) as the complement source. The concentrations of heat-inactivated mouse antiserum
in the reaction mixtures are shown on the x axes. All antisera from mice immunized with GLA-SE alone did not show
any bactericidal activity (100% survival). (Table S4A shows numerical data.)
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complement-dependent killing by sera from mice that had been immunized with the
50-g/dose schedule. All 13 immune sera, when used at final concentrations of 3.3%,
killed MS11 at 60%; 6.7% immune serum concentrations resulted in 98% killing
(Fig. 3C). Consistent with the observation that post-dose 3 sera did not possess specific
IgM against the 2C7 epitope (Fig. S3A), we did not note significant decreases in killing
of either FA1090 (Table S4B) or MS11 (Table S4C) when IgM was depleted. None of the
antisera from adjuvant control (GLA-SE alone) mice showed bactericidal activity
(100% survival) (Table S4B and Table S4C).
As shown in Fig. 4 (panels A and B show experimental challenge data with FA1090
and MS11, respectively), all three doses of TMCP2 accelerated clearance and diminished
colonization with each of the gonococcal strains over the 11-day course, compared to
the adjuvant control. The rate of decline of CFU with time (middle graphs) and the area
under the concentration-time curve analyses (right graphs) showed similar vaccine
efficacy at all three doses and against both isolates.
Efficacy of TMCP2 using a biweekly schedule. We also examined a compressed
schedule of immunization (dosing at 2-week instead of 3-week intervals). Mice were
immunized with 50 g of TMCP2 plus GLA-SE using three 50-g doses, each given
2 weeks apart. Two weeks after the third dose, mice (n  14/group) were challenged
with strain FA1090 (107 CFU). This compressed immunization regimen also effectively
attenuated gonococcal colonization (Fig. 5A) compared to GLA-SE adjuvant alone. The
mean anti-LOS level in sera from 11 fully immunized mice was 2.31 g/ml (standard
deviation, 0.68; range 1.33 to 3.59 g/ml) (Fig. 5B). Specificity of the immune responses
were shown by nonreactivity of adjuvant control sera with 2C7-positive LOS and
FIG 3 Immunogenicity and functional activity of antibodies elicited in groups of mice immunized with TMCP2/
GLA-SE to evaluate broader functional efficacy. Six-week-old female BALB/c mice were immunized with TMCP2
given at 50, 100, or 200 g per dose with GLA-SE adjuvant (5 g) every 3 weeks, or with GLA-SE alone (adjuvant
control; not shown). Each group contained 13 mice and represented mice not used for challenge studies in Fig. 4.
(A) Anti-LOS antibody levels in immune sera. Sera obtained 2 weeks after each dose were assayed for antibody
levels against N. gonorrhoeae 15253 LOS. Note the different y axes in the three graphs. None of the antisera from
mice immunized with GLA-SE alone (adjuvant control) showed measurable anti-gonococcal LOS IgG levels. (B)
Bactericidal activity of immune sera against strain FA1090. Post-dose 3 sera used at concentrations (indicated on
the x axis) of 10% (1/10 dilution), 12.5% (1/8 dilution), or 16.7% (1/6 dilution) were tested for their ability to kill N.
gonorrhoeae FA1090 using NHS (20% [vol/vol]) as the complement source. The y axis shows the percentage of
bacterial survival at 30 min relative to 0 min. (Table S4B shows the numerical data.) (C) Bactericidal activity against
strain MS11 of immune sera from mice immunized with three doses of 50 g, each given 3 weeks apart. Bactericidal
assays were performed as described in panel B, except that immune sera were tested at (lower) concentrations: 1.3,
3.3, and 6.7% with 6.7% human complement (IgG/IgM-depleted NHS [Pel-Freez]) added as a source of complement.
None of the IgM-depleted antisera from adjuvant control mice (given GLA-SE alone) showed any bactericidal
activity (100% survival). (Table S4C shows the numerical data.)
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nonreactivity of immune sera against 2C7-negative LOS purified from 15253 ΔlgtG
(Fig. S3B). All sera showed bactericidal activity (50% killing at 1:6 dilution [16.7%
antiserum concentration]) (Fig. 5C), similar to that achieved by similar or higher TMCP2
dosing administered at longer intervals (Fig. 4). IgM depletion from sera did not change
bactericidal activity significantly (Table S4D).
In a separate experiment, we immunized 5 mice with TMCP2 (50 g/dose) plus
GLA-SE, or GLA-SE alone at 0, 2, and 4 weeks and collected serum and vaginal swabs
2 weeks after the third dose for measurement of anti-LOS IgG. Anti-LOS IgG was
detected in vaginal swabs of the 5 mice given TMCP2 (see Table S5 in the supplemental
material).
DISCUSSION
In this study, we show that a candidate gonococcal peptide vaccine that elicits
bactericidal antibodies against N. gonorrhoeae significantly reduces the duration and
burden of gonococcal cervicovaginal colonization in BALB/c mice. Combining TMCP2
with GLA-SE, which elicits a Th1-biased response (22–25), evoked 2C7 epitope-specific
IgG antibody responses after immunization with three intramuscular doses. Our prior
studies using the octameric peptide forerunner of TMCP2 (13) and other studies in mice
(28) suggest that a Th1 response clears infection and induces a memory response,
which may have contributed to the efficacy of GLA-SE.
A limitation of the octameric peptide vaccine used in our previous study (13) was
heterogeneity of the molecular mass of the preparation, likely the result of formation
of inter- and intramolecular disulfide bonds. To circumvent this problem, we devised a
novel synthetic method in which each peptide subunit was first circularized with a
covalent, nonreducible thioether bond; each of the circularized subunits was then
linked to a dendrimeric Glu backbone. The resulting tetrapeptide, TMCP2, showed a
single peak on mass spectroscopy. This relatively facile synthesis process yielded a
FIG 4 Efficacy of TMCP2/GLA-SE against N. gonorrhoeae strains FA1090 and MS11 in the mouse vaginal
colonization model. Six-week-old female BALB/c mice were immunized with TMCP2 (either 50, 100, or 200 g/dose)
plus GLA-SE (5 g) or with GLA-SE alone (adjuvant control) at 0, 3, and 6 weeks. Quantitation of antibody
concentrations against 15253 LOS and serum bactericidal antibody titers in corresponding groups of mice
immunized at the same time are shown in Fig. 3. Two weeks after the last immunization, 12 mice in each group
in the diestrus phase of the estrous cycle were treated with Premarin; six mice in each of the four groups were
infected intravaginally with strain FA1090 (5  107 CFU; n  6) or with strain MS11 (4.2  107 CFU) on day 0.
Efficacy of TMCP2/GLA-SE against FA1090 and MS11 is shown in panels A and B, respectively. Sera from 13
simultaneously immunized mice in each group were used for immunogenicity studies (Fig. 4). The graphs on the
left (Kaplan-Meier analysis) show time to clearance of infection. Groups were compared using the Mantel-Cox
log-rank test. Significance was set at 0.008 (Bonferroni’s correction for 4 groups). The middle graphs show log10 CFU
versus time. Graphs on the right show bacterial burdens consolidated over time (area under the concentration-time
curve [log10 CFU] analysis). The median and 95% confidence intervals are shown for each group. The four groups
were compared using the nonparametric Kruskal-Wallis equality-of-populations rank test. The 2 test results with
ties (3 df) were 14.36 (P  0.0025) for FA1090 (A) and 13.69 (P  0.0034) for MS11 (B). Pairwise comparisons across
groups (indicated with the graphs) were made with the two-sample Wilcoxon rank-sum test and applying the
Kruskal-Wallis equality-of-populations rank test for comparisons across more than two groups.
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compound of greater than 95% purity, which is suitable for scale-up and production of
an inexpensive gonococcal vaccine candidate.
Activation of the classical pathway of complement requires engagement of the C1
complex (subunits of C1q, C1r and C1s), triggered by Fc antibody domains. Upon
binding to surfaces, Fc domains of proximate IgG molecules form ordered hexamers
through noncovalent interactions (27), which then simultaneously engage multiple
globular heads of C1q, also a hexameric molecule. Multimeric interactions between
globular domains of C1q and Fc convert otherwise low-affinity monomeric IgG Fc-C1q
associations to interactions of high avidity, which permits autocatalysis of C1r and
further complement activation. An effective bactericidal antibody requires a critical
density of surface targets to engage C1q and permit complement activation. On a
molar basis, LOS is the most abundant gonococcal outer membrane molecule and
serves as a convenient target for binding of closely spaced antibody molecules whose
Fc domains can then readily engage the C1 complex and activate complement. We
have shown that an intact complement system is necessary and sufficient for efficacy
of passively administered bactericidal MAb 2C7— given either systemically or intrav-
aginally—in the mouse vaginal colonization model (18). The importance of comple-
ment in host defenses against gonorrhea is highlighted by the observation that both
congenital and acquired defects of individual terminal components of complement
are associated with an increased incidence of disseminated gonococcal infection (DGI)
(28–31). Based on our data with MAb 2C7, we propose that attenuation of colonization
by antibodies elicited by TMCP2 vaccine also occurs via complement-dependent
FIG 5 Efficacy of TMCP2/GLA-SE against N. gonorrhoeae FA1090 in the mouse vaginal colonization model using
a biweekly 3-dose schedule. Six-week-old female BALB/c mice (n  25/group) were immunized with 50 g/dose
TMCP2 plus GLA-SE (5 g) or with GLA-SE alone (adjuvant control) at 0, 2, and 4 weeks. Two weeks after the last
immunization, 14 mice in each group in the diestrus phase of the estrous cycle were treated with Premarin and
infected intravaginally with strain FA1090 (107 CFU) on day 0. Sera from the remaining 11 mice in each group was
collected by cardiac puncture for use in immunologic studies. (A) The graph on the left shows time to clearance
of infection (Kaplan-Meier analysis; groups were compared using the Mantel-Cox log-rank test). The graph in the
middle shows log10 CFU versus time. The median and 95% confidence intervals are shown for each group. The
graph to the right shows bacterial burdens consolidated over time (area under the concentration-time curve [log10
CFU] analysis). Pairwise comparisons between groups were made with the two-sample Wilcoxon rank-sum
(Mann-Whitney) test. (B) Anti-LOS antibody levels in immune sera. Sera obtained 2 weeks after the 3rd vaccine dose
were assayed for antibody levels against N. gonorrhoeae 15253 LOS. None of the antisera from mice immunized
with GLA-SE alone (adjuvant control) showed measurable anti-gonococcal LOS IgG levels, and none of the immune
sera reacted with 2C7-negative LOS (Fig. S3B). (C) Bactericidal activity of immune sera. Sera obtained 2 weeks after
the 3rd vaccine dose used at concentrations of 10% (1/10 dilution), 12.5% (1/8 dilution) or 16.7% (1/6 dilution)
(concentrations indicated on the X-axis) were tested for their ability to kill N. gonorrhoeae FA1090 using human
complement (16.7% [vol/vol]) as the complement source. y axis, % bacterial survival at 30 min relative to 0 min.
None of the IgM-depleted antisera from adjuvant control mice (given GLA-SE alone) showed any bactericidal
activity (100% survival [Table S4D]).
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bactericidal antibody activity. A vaccine candidate developed by Liu and colleagues
that comprises gonococcal outer membrane vesicles plus microencapsulated
interleukin-12 (IL-12) given intravaginally requires B cell activity, presumably to produce
antibodies (32); however, a requirement for complement has not been shown.
Similar to our findings, no other gonococcal vaccine candidates tested in the
cervicovaginal colonization model in estradiol-treated mice show sterilizing immunity
(26, 32, 33). Immunomodulatory effects of estrogen (34) may curb immune defenses
that are important to clear N. gonorrhoeae. Studies over 50 years ago showed that
the activity of terminal complement components in male mice exceeds, by 8- to10-fold,
activity in female mice (35). Administration of testosterone increases complement
activity; estrogen has the opposite effect (36). Therefore, a vaccine antibody response
that requires terminal complement for its efficacy may simultaneously require waning
of the suppressive effects of estrogen on synthesis of terminal complement compo-
nents before full bactericidal activity is restored.
A retrospective epidemiologic analysis showed that a detergent-extracted menin-
gococcal outer membrane vesicle (dOMV) vaccine called MeNZB designed and imple-
mented in a widespread vaccination program to control an epidemic of group B
meningococcal disease in New Zealand, showed diminished coverage in populations
subsequently infected with N. gonorrhoeae— calculated as 31% effectiveness of MenZB
in decreasing gonococcal infection—reduced to 14% in populations coinfected with N.
gonorrhoeae and chlamydia, a frequent clinical occurrence (37–39). Meningococci and
gonococci share several similarities, and it is possible that one or more proteins in
MeNZB that cross-react with N. gonorrhoeae may elicit protective immune responses.
Individuals administered a licensed group B meningococcal vaccine, Bexsero, which
contains 5 recombinant meningococcal protein antigens in addition to the same dOMV
that constitutes MeNZB (40), elicit antibodies, immunochemically, that cross-react with
N. gonorrhoeae (41). Antibodies elicited by immunizing mice with Bexsero or MeNZB
were reported to support bactericidal activity against N. gonorrhoeae (42). However, a
separate study did not reveal bactericidal antibody activity against N. gonorrhoeae
FA1090 in immune sera from individuals vaccinated with Bexsero (20). How MeNZB
provides protection against gonorrhea remains unclear; possible additional mecha-
nisms may include reduction of adhesion of N. gonorrhoeae to human cervical cells (42).
Currently, several gonococcal vaccine candidates are undergoing preclinical evaluation
(reviewed in reference 5), some of which elicit bactericidal activity (43–45).
Three glycosyltransferase genes (lgtA, lgtC, lgtD involved in LOS biosynthesis are
phase-variable because of slipped-strand mispairing of homopolymeric poly(G) tracts in
their open reading frames (46, 47); a fourth, lgtG, containing a poly(C) tract, is also phase
variable (12, 46, 48–50). Expression of the 2C7 epitope requires lgtG to be phase varied
“on”; the expression status of the three other lgt genes modulates binding of MAb 2C7
to LOS (11). As discussed above, the 2C7 LOS epitope is expressed almost universally in
vivo and by minimally passaged isolates. The 2C7 epitope was identified in 64 of 68
(94%) gonococcal isolates examined directly in cervical secretions from women in a
sexually transmitted disease clinic in Boston in the 1990s and 96 of 101 (95%) of
randomly chosen minimally (second-passage) isolates (7). Recently, we reported that
100% of 75 minimally passaged isolates from China also expressed the 2C7 epitope
(15). Importantly, MAb 2C7 was bactericidal (50% killing) against each of 62 isolates
tested in complement-dependent bactericidal assays, including strains that expressed
low levels of the epitope (15). Because LOS is the most abundant outer membrane
molecule on gonococci, expression of the 2C7 epitope on even a small fraction of LOS
may permit binding of antibody at a density sufficient to engage the C1 complex and
activate the classical pathway. We speculate that widespread expression of this epitope
results from the gonococcal ability to sialylate lactose expressed from HepII, which
facilitates engagement of Siglec receptors (16). Many Siglec receptors signal through
their immunoreceptor tyrosine-based inhibitory motif (ITIM) tails (51) to dampen host
inflammatory responses that otherwise sense invading pathogens (52, 53). Neu5Ac
(sialic acid) that caps lactose from HepII also inhibits complement C3 deposition on the
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bacterial surface (15). Genetic deletion of lgtG or lst (sialyltransferase) from a strain
whose only site for sialylation is the terminal Gal of HepII lactose markedly attenuates
the ability of N. gonorrhoeae to colonize the vagina of estradiol-treated mice (13, 15).
Additional evidence for the importance of lgtG expression was provided by Lam and
Gray-Owen, who showed that serial passage of N. gonorrhoeae in mice was accompa-
nied by increased fitness of bacteria with each generation—i.e., an increasing fraction
of mice could be infected with bacteria recovered from each successive mouse
passage. Intriguingly, there was a reproducible positive selection for gonococcal
variants with lgtG “on” (54). Resistance to antibodies elicited by a “2C7 vaccine”
would require lgtG to be turned completely “off.” Based on the accumulated
evidence from studies of minimally passaged isolates, bacteria examined directly ex
vivo from humans (without passage on media), and studies in mice, as discussed
above, we propose that mutations in gonococci that eliminate 2C7 LOS epitope
would render the organism less fit and avirulent. From a public health perspective,
translation to a decrease in burden and duration of infection can have profound
effects on disease pathology and transmission. In conclusion, TMCP2 represents an
important step forward in the development of a safe, economical, and effective
gonococcal vaccine or subcomponent thereof.
MATERIALS AND METHODS
Bacterial strains. N. gonorrhoeae strains FA1090 (Opa Pil) (55), MS11 (Opa Pil) (56), 15253 (57),
and 15253 ΔlgtG (isogenic mutant of 15253 with lgtG deleted, which does not react with MAb 2C7) (15)
have been described previously.
Purification of LOS. LOS was purified from strains 15253 and 15253 ΔlgtG using the hot water
phenol extraction method (58).
Materials for production of TMCP2. The 4 branched reverse MAP (multiple antigenic peptide) was
synthesized using a solid-phase approach for the thioether peptide component and a classical solution
phase method for production of the reverse MAP core and final tetra MAP construct. Briefly, the thioether
monomer was synthesized on an Fmoc-Lys-Wang resin using standard Fmoc-tBu amino acid derivatives.
At the completion of assembly of the protected linear peptide sequence: H-Gly-Pro-(Ile-Pro-Val-Leu-Asp-
Glu-Asn-Gly-Leu-Phe-Ala-Pro)-Gly-Pro-Cys-Lys-OH, bromoacetic acid was coupled to the N terminus via
symmetric anhydride coupling. The peptide Br-Ac-Gly-Pro-Ile-Pro-Val-Leu-Asp-Glu-Asn-Gly-Leu-Phe-Ala-
Pro-Gly-Pro-Cys-Lys-OH was cleaved from the solid support and simultaneously deprotected using
trifluoroacetic acid containing H2O and triisopropyl silane as cationic scavengers. The crude linear
peptide was purified using preparative HPLC and subsequently cyclized by dilution into 1% Na2CO3
buffer to a concentration of 0.3 mg/ml. Cyclization was completed at 18 h, and the cyclic thioether
peptide (structure indicated as “MAP Core Peptide 2” in Fig. 1A) was purified via preparative
RP-HPLC. Fractions that had a purity of 90% by analytical HPLC were pooled and lyophilized. The
cyclic thioether monomer peptide was characterized using ESI-MS (calculated m/z  1,864.17;
measured m/z  1,864.88).
The reverse MAP core construct was synthesized starting with Ac--Ala-OH. H-Glu(OBzl)2 was coupled
to the Ac--Ala-OH using diphenylphosphoryl azide. The benzyl groups were liberated via catalytic
hydrogenation. Ac--Ala-Glu-OH was reacted subsequently with 2 equivalents of H-Glu(OBzl)2. Benzyl
groups were removed again via catalytic hydrogenation. The final reverse tetra-MAP core peptide
Ac--Ala-Glu[Glu-OH]2 (“Reverse MAP Core” in Fig. 1A) was isolated and characterized by ESI MS:
calculated m/z  519.19 and measured m/z  519.22. This compound was subsequently activated to the
tetra NHS ester in the presence of diisopropyl carbodiimide.
The tetra-MAP construct TCMP2 was synthesized by adding 4.2 equivalents of the cyclic thioether
MAP core peptide 2 to the reverse MAP core: Ac--Ala-Glu[Glu(OSu)2]2. Following coupling for 20 h, the
crude peptide tetra-MAP TMCP2 was isolated by preparative RP-HPLC. The resulting fractions with a
purity of 95% were pooled and lyophilized. The final product, TCMP2, was isolated and characterized
by ESI MS. The structure for TMCP2 is shown in Fig. 1A. Figure S4 shows a summary of the synthesis
procedure.
Immunization of mice. Six-week-old female BALB/c mice were immunized with TMCP2 (dose
specified for each experiment) and GLA-SE (5 g) as the adjuvant. Control mice received GLA-SE adjuvant
alone. Sera were collected 2 weeks after each immunization.
ELISA to measure anti-LOS antibody levels. Microtiter wells were coated with LOS purified from
15253 or 15253 ΔlgtG (80 g/ml) in phosphate-buffered saline (PBS) as described previously (13). Serial
dilutions of immune sera were dispensed into wells, and bound anti-LOS antibody was disclosed with
anti-mouse IgG conjugated to alkaline phosphatase. A standard curve for mouse IgG was generated by
coating wells with anti-mouse IgG (Sigma) and pure mouse IgG (Sigma), also as described previously (13).
Mouse IgM bound to LOS was detected with anti-mouse IgM conjugated with alkaline phosphatase
(Sigma).
Inhibition ELISA. In order to compare antigenicity of MAP core peptide 2 (monomeric cyclic CP2)
and composite TMCP2 compounds with LOS that expresses the 2C7 epitope, we performed inhibition
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ELISA using mouse MAb 2C7 (7, 17) reacted with the individual compounds to assess inhibition of
binding (residual binding) of MAb to LOS by each compound. Microtiter wells were coated with LOS
(80 g/ml in PBS) purified from N. gonorrhoeae strain 15253. Wells were washed and blocked with
PBS– 0.05% Tween 20. MAb 2C7 (0.04 g/ml), either alone or containing monomeric cyclic peptide CP2
(1.07 to 1070 M) or composite TMCP2 (at concentrations ranging from 0.25 to 250 M), was dispensed
into LOS-coated wells. Residual binding of 2C7 MAb was measured with anti-mouse IgG conjugated to
alkaline phosphatase.
Bound IgG was quantitated using a mouse IgG standard curve (17), and the percentage of inhibition
was determined compared to reaction mixtures that contained LOS (full inhibition).
Depletion of mouse IgM. Because earlier we had observed that sera from naive and mice given
adjuvant alone manifest bactericidal activity mediated by IgM (see Results), we depleted mouse IgM from
sera collected as part of antigen optimization and adjuvant selection studies (described above). Sera from
mice were mixed with anti-mouse IgM-agarose (Sigma; binding capacity, 0.4 mg/ml) (1 volume of
packed agarose to 1 volume of serum diluted 1:1) in a 2.0-ml microspin filter column (Costar) with a pore
size of 0.22 m for 15 min at 22°C. Filter-sterilized IgM-depleted sera were collected by centrifugation of
the mixture at 1,000  g for 2 min and heat inactivated (56°C for 30 min) to eliminate intrinsic
complement activity in mouse serum prior to use in serum bactericidal assays where human complement
was substituted.
Serum bactericidal assays. Serum bactericidal assays were performed as described previously (59).
Bacteria that had been harvested from an overnight culture on chocolate agar plates were repassaged
onto fresh chocolate agar and allowed to grow for 6 h at 37°C in an atmosphere containing 5% CO2.
Bacteria were then suspended in Hanks’ balanced salt solution (HBSS) containing 1 mM MgCl2 and
0.15 mM CaCl2 (HBSS) for use in serum bactericidal assays. About 2,000 CFU was incubated with serial
dilutions of immune mouse sera (heat-inactivated and IgM depleted) in the presence or absence of 20%
normal human serum (NHS) as a source of human complement. Serum bactericidal assays with strain
MS11 were performed with IgG- and IgM-depleted NHS (human complement; Pel-Freez) because MS11
is susceptible to killing by NHS. The final volumes of bactericidal reaction mixtures were 150 l. Aliquots
of 25-l reaction mixtures were plated onto chocolate agar in duplicate at the beginning of the assay
(time zero [t0]) and after incubation at 37°C for 30 min (t30). Survival was calculated as the number of
viable colonies at t30 relative to t0.
Mouse protection experiments. Use of animals in this study was performed in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health (60). The protocol was approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Massachusetts Medical School. The BALB/c mouse model of vaginal
colonization described by Jerse was used (61). Two weeks after the last immunization, mice in the
diestrus phase of the estrous cycle were started on treatment (that day) with 0.1 mg Premarin (Pfizer) in
200 l of water, given subcutaneously on each of 3 days: days 2, 0, and 2 (before, the day of, and after
gonococcal inoculation) to prolong the estrus phase of the reproductive cycle and promote susceptibility
to N. gonorrhoeae infection. Antibiotics (vancomycin and streptomycin) ineffective against N. gonor-
rhoeae were also used to reduce competitive microflora (62). Mice were infected on day 0 with either
strain FA1090 or MS11 (inoculum specified for each experiment). Vaginas were swabbed daily to
enumerate gonococcal CFU.
Statistical analyses. Experiments that compared clearance of N. gonorrhoeae in independent groups
of mice estimated and tested three characteristics of the data (13): time to clearance; longitudinal trends
in mean log10 CFU and the cumulative CFU as area under the concentration-time curve (AUC). Statistical
analyses were performed using mice that initially yielded bacterial colonies on day 1 and/or 2. Median
time to clearance was estimated using Kaplan-Meier survival curves; times to clearance were compared
between groups using the Mantel-Cox log-rank test. Mean log10 CFU trends over time were compared
between groups using a linear mixed model with mouse as the random effect using both a random
intercept and a random slope. A quadratic or cubic function in time was determined to provide the best
fit; random slopes were linear in time. A likelihood ratio test was used to compare nested models (with
and without the interaction term of group and time) to test whether the trend differed over time
between the two groups. The mean AUC (log10 CFU versus time) was computed for each mouse to
estimate the bacterial burden over time (cumulative infection); the means under the curves were
compared between groups using the nonparametric two-sample Wilcoxon rank-sum (Mann-Whitney)
test because distributions were skewed or kurtotic. The Kruskal-Wallis equality-of-populations rank test
was also applied to compare more than two groups in an experiment.
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